admin – Page 62 – Get News Story

Metastatic Colorectal Cancer Pipeline Shows Potential with Active Contributions from 150+ Key Companies | DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 180+ pipeline drugs in Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Metastatic Colorectal Cancer pipeline products in this space.

Download DelveInsight’s comprehensive Metastatic Colorectal Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

On May 29, 2026- AbbVie initiated a phase 2 study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
On May 20, 2026- M.D. Anderson Cancer Center announced a phase II clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.
On May 18, 2026- Riboscience LLC conducted a Phase 2a study, subjects must have failed, been unable to tolerate, or declined to take known standard-of-care (SOC) therapies. Subjects must have measurable disease per RECIST 1.1, an Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2, and predicted life expectancy of greater or equal to 3 months.
On May 14, 2026- Taizhou Hanzhong biomedical Co. Ltd initiated a phase III study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator’s Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).
On May 08, 2026- EMD Serono Research & Development Institute Inc. conducted a phase 3 study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.
DelveInsight’s Metastatic Colorectal Cancer pipeline report depicts a robust space with 150+ active players working to develop 180+ pipeline therapies for Metastatic Colorectal Cancer treatment.
The leading Metastatic Colorectal Cancer Companies such as Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
Promising Metastatic Colorectal Cancer Therapies such as Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.

Discover how the Metastatic Colorectal Cancer treatment paradigm is evolving @ Metastatic Colorectal Cancer Clinical Trials and Studies

Metastatic Colorectal Cancer Overview

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.

Metastatic Colorectal Cancer Emerging Drugs Profile

HLX10 (Serplulimab) + HLX04: Shanghai Henlius Biotech

HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. HLX04 is a bevacizumab biosimilar developed by Henlius independently in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative), which can be used in the treatment of advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). HLX04 can block the interaction between vascular endothelial growth factor (VEGF) and its receptors by binding with VEGF specifically, which then inhibits tumour angiogenesis and thus suppressing the growth and metastases of tumours.

Lenvatinib: Eisai Inc.

LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below. Currently the drug is in Phase III stage of its development for the treatment of metastatic colorectal cancer.

PEPI1018: Treos Bio

PolyPEPI-1018, Treos’ lead product candidate, is an off-the-shelf immunotherapy in clinical development for the treatment of metastatic colorectal cancer, co-developed with a candidate companion diagnostic. The therapy is in development as a first-line maintenance therapy and as a third-line treatment. The companion diagnostic uses Treos’ proprietary PASCal computational tool to identify Personal EPItopes (PEPIs) that are likely to induce antigen-specific T Cell responses in a patient. In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. PolyPEPI1018 was designed to induce polyvalent T cell responses in a large subpopulation of CRC patients using its PEPI TestTM platform which identifies Personal EPItopes (PEPIs) that are likely to induce antigen-specific T cell responses in a subject. Currently the drug is in Phase II stage of its development for the treatment of metastatic colorectal cancer.

AUM-001: AUM Biosciences

AUM001 is a highly selective translation inhibitor. It selectively inhibits MNK 1/2 and thereby blocks phosphorylation of eIF4E. This, in turn, interferes with CAP mediated RNA translation, thereby impairing growth signals involved in cancer development, progression, and resistance to therapies. MNK is important in tumor microenvironment (TME) regulation, shifting the balance towards tumor inhibition. Moreover, inhibition of MNK kinases decreases the production of the pro-inflammatory cytokines like TNFα and IL-6, suggesting that MNK kinases and their substrates (eIF4E, hnRNP A1, Spry1/2) play a pivotal role in regulating the innate and adaptive immune compartment. This has the potential to turn “cold” tumors “hot”, increasing the proportion of tumors susceptible to immunotherapies. AUM001 demonstrated encouraging safety, tolerability and target engagement as a monotherapy in two Phase I clinical trials. The global Phase II trial is being conducted in collaboration with MSD, a tradename of Merck & Co., Inc., pursuant to a clinical trial collaboration and supply agreement for KEYTRUDA. Currently, the drug is in the Phase II stage of its development for the treatment of metastatic Colorectal Cancer.

DKN-01: Leap Therapeutics, Inc.

Sirexatamab (DKN-01) is an investigational humanized IgG4-kappa monoclonal antibody that targets Dickkopf-related protein 1 (DKK1), a modulator of the Wnt signaling pathway. Overexpression of DKK1 has been associated with tumor progression and poor prognosis in various cancers, including colorectal cancer (CRC). In preclinical studies, DKK1 has been identified as a resistance mechanism to commonly used chemotherapy in colorectal cancer models. By binding to and neutralizing DKK1, sirexatamab aims to restore normal Wnt signaling, thereby inhibiting tumor growth and potentially enhancing the efficacy of other anticancer therapies. Currently the drug is in Phase II stage of its development for the treatment of Metastatic Colorectal cancer.

RO7122290: Hoffmann-La Roche

RO7122290is a novel 4-1BB agonist that targets fibroblast activation protein-a (FAP), which is abundantly expressed by cancer-associated fibroblasts in many tumors. Simultaneous binding of FAP and 4-1BB results in clustering and activation of T- and natural killer cells at the tumor site and simultaneous antitumor activity, which has been demonstrated in preclinical models. Upon administration, the FAP/4-1BB-targeting fusion protein RO7122290 targets and binds to both FAP, localized on tumor stromal cells, and 4-1BB, expressed on a variety of leukocyte subsets including activated T-lymphocytes and natural killer (NK) cells. The simultaneous binding of FAP and 4-1BB results in local clustering of FAP-expressing tumor stromal cells and 4-1BB-expressing T-cells, and local immune cell activation through the promotion of T-cell activation, cytokine release and T-cell-mediated anti-tumor immune responses. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity. FAP is abundantly expressed by cancer-associated fibroblasts in the majority of solid tumors. The drug is currently in Phase I/II stage of its development for the treatment of metastatic colorectal cancer.

E7386: Eisai

E7386 is a CBP / β-catenin inhibitor that inhibits protein-protein interactions between the transcription coactivator CBP and β-catenin, and regulates the Wnt signaling-dependent gene expression. Since E7386 acts on the CBP / β-catenin transcription complex located at the most downstream of the Wnt signaling, it is expected to inhibit not only ligand-dependent activation but also activation caused by gene mutations in Wnt signaling factors such as adenomatous polyposis coli (APC) and β-catenin. E7386 is an orally active selective inhibitor of the interaction between β-catenin and CREB binding protein, which is part of the Wnt/β-catenin signaling pathway, disrupts the Wnt/β-catenin signaling pathway in HEK293 and adenomatous polyposis coli (APC)-mutated human gastric cancer ECC10 cells. In preclinical models, E7386 has demonstrated antitumor activity against mouse mammary tumors developed in Mouse Mammary Tumor Virus (MMTV)-Wnt1 transgenic mice. Currently, the drug is in the Phase I/II stage of its development for the treatment of Metastatic Colorectal Cancer.

The Metastatic Colorectal Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Colorectal Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Colorectal Cancer Treatment.
Metastatic Colorectal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Colorectal Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Colorectal Cancer pipeline @ Metastatic Colorectal Cancer Unmet Needs

Metastatic Colorectal Cancer Companies

Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.

Metastatic Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Colorectal Cancer Therapies @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Colorectal Cancer Pipeline Report

Coverage- Global
Metastatic Colorectal Cancer Companies-Shanghai Henlius Biotech, Eisai Inc., Treos Bio, AUM Biosciences, Leap Therapeutics, Inc., Hoffmann-La Roche, Replimune, Qilu Pharmaceutical, Lutris Pharma, Ipsen, Bold Therapeutics, Pacylex Pharmaceuticals, FivepHusion, SystImmune, Inspirna, Inc., Sapience Therapeutics, Daiichi Sankyo, Hutchmed, Merus N.V. and others.
Metastatic Colorectal Cancer Therapies- Regorafenib, Cyclophosphamide, Capecitabine, NV1020, MRTX849, Pembrolizumab, Cetuximab, erlotinib, FOLFOX, and others.
Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Colorectal Cancer drug development? @ Metastatic Colorectal Cancer Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Metastatic colorectal cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Metastatic colorectal cancer Collaboration Deals
Late Stage Products (Phase III)
Lumakras (sotorasib): Amgen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Axitinib: Pfizer
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NX 1607: Nurix Therapeutics Inc
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Metastatic colorectal cancer Key Companies
Metastatic colorectal cancer Key Products
Metastatic colorectal cancer- Unmet Needs
Metastatic colorectal cancer- Market Drivers and Barriers
Metastatic colorectal cancer- Future Perspectives and Conclusion
Metastatic Colorectal Cancer Analyst Views
Metastatic Colorectal Cancer Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Colorectal Cancer Pipeline Shows Potential with Active Contributions from 150+ Key Companies | DelveInsight

Exosomes Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Exosomes Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Exosomes Pipeline? @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight

Key Takeaways from the Exosomes Pipeline Report

On March 23, 2026- Direct Biologics LLC initiated a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
DelveInsight’s Exosomes Pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
The leading Exosomes Companies such as Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.
Promising Exosomes Therapies such as Olmutinib, Zofin, AGLE-102, and others.

Want to know which companies are leading innovation in Exosomes? @ Exosomes Clinical Trials Assessment

The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.

Exosomes Overview

Exosomes are small extracellular vesicles (≈40–160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell–cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway. Owing to these properties, exosomes are being actively explored for diagnostic and therapeutic applications, particularly in drug discovery. They are commonly isolated using techniques such as differential centrifugation and polymer-based precipitation.

Exosomes Emerging Drugs Profile

CAP-1002: Capricor Therapeutics

Capricor’s CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marbán. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.

Debamestrocel: BrainStorm Cell Therapeutics

Debamestrocel (NurOwn) consists of autologous bone marrow–derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient’s own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.

AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.

RioMSK001: RION

RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company’s pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.

HEPATOSOME: ExoStemTech

HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.

If you’re tracking ongoing Exosomes Clinical trials, this press release is a must-read @ Exosomes Treatment Drugs

The Exosomes Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

Exosomes Companies

Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Exosomes Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

From emerging drug candidates to competitive intelligence, the Exosomes Pipeline Report @ Exosomes Market Drivers and Barriers, and Future Perspectives

Scope of the Exosomes Pipeline Report

Coverage- Global
Exosomes Companies- Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.
Exosomes Therapies- Olmutinib, Zofin, AGLE-102, and others.
Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Exosomes Treatment landscape in this detailed analysis @ Exosomes Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Exosomes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Exosomes – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
RioMSK001: RION
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
HEPATOSOME: ExoStemTech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
Exosomes Key Companies
Exosomes Key Products
Exosomes – Unmet Needs
Exosomes – Market Drivers and Barriers
Exosomes – Future Perspectives and Conclusion
Exosomes Analyst Views
Exosomes Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/exosomes-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Exosomes Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

Ulcerative Colitis Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Ulcerative Colitis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Ulcerative Colitis Treatment Landscape @ https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight

Key Takeaways from the Ulcerative Colitis Pipeline Report

On May 28, 2026- Sanofi announced a Phase 2 study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
On May 28, 2026- AbbVie conducted a phase 3 study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based maintenance regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Around 120 pediatric participants with UC will be enrolled at around 80 sites worldwide.
On May 27, 2026- Bristol-Myers Squibb initiated a phase 2/3 study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
On May 26, 2026- Merck Sharp & Dohme LLC initiated a phase 2a study is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week.
On May 22, 2026- MRM Health NV conducted a phase 2 study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects. In this study, 2 different doses will be tested, and long-term treatment effects will be investigated.
On May 22, 2026- Eli Lilly and Company announced a phase 2 study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis. Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.
On May 22, 2026- Alfasigma S.p.A conducted a study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative colitis (UC).
DelveInsight’s Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment.
The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.

Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment

The Ulcerative Colitis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ulcerative Colitis Pipeline Report also highlights the unmet needs with respect to the Ulcerative Colitis.

Ulcerative Colitis Overview

Ulcerative colitis is an idiopathic inflammatory condition of the colon that results in diffuse friability and superficial erosions on the colonic wall associated with bleeding. It is the most common form of inflammatory bowel disease worldwide. It characteristically involves inflammation restricted to the mucosa and submucosa of the colon. Typically, the disease starts in the rectum and extends proximally in a continuous manner. In the United States, the disease accounts for a quarter-million provider visits annually, and medical costs directly related to the disease are estimated to exceed four billion dollars annually. The specific cause of inflammatory bowel disease is not known.

Ulcerative Colitis Emerging Drugs Profile

Obefazimod: Abivax

Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis.

ABBV-668: AbbVie

ABBV-668 is under development for the treatment of crohn’s disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

TEV-48574: Teva Pharmaceutical

Anti-TL1A (TEV-’574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-’574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-’574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn’s disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-’574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis.

SOR102: Sorriso Pharmaceuticals

SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis.

Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs

The Ulcerative Colitis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.
Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market

Ulcerative Colitis Companies

Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.

Ulcerative Colitis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Ulcerative Colitis Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives

Scope of the Ulcerative Colitis Pipeline Report

Coverage- Global
Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others.
Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others.
Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies

Table of Contents

Introduction
Executive Summary
Ulcerative Colitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ulcerative Colitis– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative Colitis Collaboration Deals
Late Stage Products (Preregistration)
Mirikizumab: Eli Lilly and Company
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Obefazimod: Abivax
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABBV-668: AbbVie
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SOR102: Sorriso Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Ulcerative Colitis Key Companies
Ulcerative Colitis Key Products
Ulcerative Colitis- Unmet Needs
Ulcerative Colitis- Market Drivers and Barriers
Ulcerative Colitis- Future Perspectives and Conclusion
Ulcerative Colitis Analyst Views
Ulcerative Colitis Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ulcerative Colitis Clinical Trial Pipeline Accelerates as 70+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Type 1 Diabetes Clinical Trial Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Type 1 Diabetes Pipeline Insight, 2026” report provides comprehensive insights about 85+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight

Key Takeaways from the Type 1 Diabetes Pipeline Report

On May 29, 2026- SAb Biotherapeutics Inc. conducted a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
On May 29, 2026- National Institute of Diabetes and Digestive and Kidney Diseases conducted a phase 2 study has a total sample size of 78 participants. Of that 78, 52 participants will receive active treatment, and a total of 26 participants will receive placebo. Participants will receive 12 months of active treatment with abrocitinib, ritlecitinib, or placebo with up to 12 months of additional follow-up. During the study, participants will undergo frequent assessments of their insulin production, immunologic status, overall health and well-being and diabetes care.
On May 22, 2026- Eli Lilly and Company initiated a phase 3 study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
On May 22, 2026- Mannkind Corporation announced a phase 3 clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 10 to
On May 22, 2026- Sanofi initiated a phase 3 study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.
DelveInsight’s Type 1 Diabetes pipeline report depicts a robust space with 85+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
The leading Type 1 Diabetes Companies such as Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
Promising Type 1 Diabetes Pipeline Therapies such as Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.

Stay informed about the cutting-edge advancements in Type 1 Diabetes treatments @ Type 1 Diabetes Clinical Trials Assessment

The Type 1 Diabetes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Type 1 Diabetes Pipeline Report also highlights the unmet needs with respect to the Type 1 Diabetes.

Type 1 Diabetes Overview

Type 1 diabetes is an autoimmune disease where the body’s immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This results in a complete lack of insulin production, which is required for the body to regulate blood sugar levels. The exact cause of this autoimmune destruction is unknown, but it is believed to involve a combination of genetic and environmental factors.

Type 1 Diabetes Emerging Drugs Profile

Insulin Efsitora Alfa: Eli Lilly and Company

LY3209590 “”Insulin Efsitora Alfa”” is a biologic entity comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Type 1 Diabetes.

Stem Cell Educator therapy: Throne Biotechnologies

Throne’s Stem Cell Educator Therapy is designed to reverse the root causes of autoimmune diseases, such as diabetes and alopecia, by fundamentally “resetting” the immune system through a one-time dialysis-like treatment using CB-SC stem cells. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of patients with Type 1 Diabetes.

Frexalimab: Sanofi

Frexalimab (SAR441344) is a potentially first-in-class second generation investigational anti-CD40L antibody that blocks the costimulatory CD40/CD40L pathway which is important for activation and function of adaptive (T and B cells) and innate (macrophages/microglia and dendritic cells) immunity. Through this unique upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte depletion. Sanofi is developing frexalimab under an exclusive license from ImmuNext. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Type 1 Diabetes.

VX-880: Vertex Pharmaceuticals

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. It is being evaluated for patients who have type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 is being investigated as an infusion into the hepatic portal vein and requires immunosuppressive therapy to protect the islet cells from immune rejection. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Type 1 Diabetes.

MTX-101: Mozart Therapeutics

MTX-101 is a bispecific autoimmune checkpoint inhibitor. Its dual configuration binds the CD8 Treg receptors, KIR and CD8, to selectively activate CD8 Treg and enhance MTX-101’s specificity, respectively. MTX-101 is designed to restore CD8 Treg functionality and the cytolytic elimination of pathogenic CD4 T cells. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Type 1 Diabetes.

Learn more about Type 1 Diabetes Drugs opportunities in our groundbreaking Type 1 Diabetes research and development projects @ Type 1 Diabetes Unmet Needs

The Type 1 Diabetes Pipeline Report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Type 1 Diabetes with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Type 1 Diabetes Treatment.
Type 1 Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Type 1 Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Type 1 Diabetes market.

Type 1 Diabetes Companies

Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Type 1 Diabetes Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Discover the latest advancements in Type 1 Diabetes treatment by visiting our website @ Type 1 Diabetes Market Drivers and Barriers, and Future Perspectives

Scope of the Type 1 Diabetes Pipeline Report

Coverage- Global
Type 1 Diabetes Companies- Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk and others.
Type 1 Diabetes Pipeline Therapies- Subetta, ORMD 0801, LY900014, Ladarixin, Technosphere Insulin, BMF-219, ASP1941, VX-264, Zenapax, Ipragliflozin, Glargine, LY2963016 and others.
Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Type 1 Diabetes Pipeline on our website, @ Type 1 Diabetes Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Type 1 Diabetes: Overview
Pipeline Therapeutics
Therapeutic Assessment
Type 1 Diabetes– DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
Teplizumab: Provention Bio
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TTP 399: Novo Nordisk
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SBP 101: Takeda Oncology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Eflornithine oral: Panbela Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Type 1 Diabetes Key Companies
Type 1 Diabetes Key Products
Type 1 Diabetes- Unmet Needs
Type 1 Diabetes- Market Drivers and Barriers
Type 1 Diabetes- Future Perspectives and Conclusion
Type 1 Diabetes Analyst Views
Type 1 Diabetes Key Companies
Appendix

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/type-1-diabetes-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 1 Diabetes Clinical Trial Pipeline Gains Momentum: 85+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Global Eosinophilic Esophagitis (EoE) Market to Witness Significant Growth Through 2030, Driven by Advancements in Diagnostics and Emerging Biologic Therapies, Reveals DelveInsight

DelveInsight’s “Eosinophilic Esophagitis (EoE) Market Insights, Epidemiology, and Market Forecast–2030” report provides a comprehensive analysis of the disease landscape, epidemiology trends, current treatment practices, emerging therapies, market dynamics, and competitive intelligence across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The global Eosinophilic Esophagitis (EoE) market is expected to experience substantial growth during the forecast period 2018–2030, fueled by increasing disease awareness, advancements in diagnostic technologies, rising healthcare expenditure, and ongoing development of targeted biologic therapies. According to DelveInsight’s latest report, the EoE market across the seven major markets (7MM) was valued at approximately USD 430.9 million in 2020 and is anticipated to witness significant transformation over the coming years.

Download the free sample report to explore the Eosinophilic Esophagitis market in detail: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights From the Eosinophilic Esophagitis Market Report

The Eosinophilic Esophagitis market is projected to expand steadily through 2030 due to increasing disease prevalence, improved diagnostic capabilities, and the emergence of novel biologic therapeutic approaches aimed at enhancing efficacy and improving patient outcomes.

The market size of Eosinophilic Esophagitis across the 7MM reached approximately USD 430.9 million in 2020 and is expected to grow significantly during the forecast period 2018–2030.

Key companies operating in the Eosinophilic Esophagitis market include Takeda/Shire, Bristol-Myers Squibb, Regeneron Pharmaceuticals/Sanofi, AstraZeneca, Allakos, and Ellodi Pharmaceuticals, among other major therapeutics providers.

The report highlights increasing research efforts focused on improving treatment efficacy, developing targeted biologic therapies, and optimizing treatment algorithms combining diet, drugs, and dilation (“3Ds”).

Ongoing developments in biologic immunotherapies, anti-inflammatory agents, and enhanced diagnostic methodologies are expected to reshape the EoE treatment landscape in the coming years.

Understanding Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis (EoE) is a chronic, local immune-mediated esophageal disease clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. It is a distinct disease entity that was first described in 1978, misinterpreted as achalasia, and formally recognized as a distinct condition more than a decade later.

The disease is characterized by major symptoms including heartburn, regurgitation, esophageal stenosis, and dysphagia, with greater prevalence in young adults and children. Established risk factors include male gender, Caucasian race, and atopy, with genetic predisposition supported by family clustering and specific genetic polymorphisms.

The pathophysiology of EoE is complex, involving a network of various cells and molecules including eosinophils, Th2 cells, thymic stromal lymphopoietin (TSLP), transforming growth factor-beta 1 (TGF-β1), and interleukin-13 (IL-13). Environmental factors, including the timing and nature of food and aeroallergen exposure during immune system development, contribute significantly to disease manifestation.

Access a free sample PDF to explore the EoE therapeutic landscape: Eosinophilic Esophagitis Epidemiology Insights

Eosinophilic Esophagitis (EoE) Epidemiology Insights

The epidemiology section of the report provides detailed historical and forecasted trends of EoE across the seven major markets from 2018 to 2030.

Key epidemiological insights include:

Total diagnosed prevalent cases of EoE in the 7MM
Gender-specific diagnosed prevalent cases
Age-specific diagnosed prevalent cases
Country-wise epidemiological analysis across the United States, EU5, and Japan

The report enables stakeholders to better understand disease burden, patient demographics, and evolving epidemiological trends supporting strategic planning and commercial decision-making.

The report offers a detailed overview of current diagnostic and treatment practices for EoE: https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Diagnosis

Diagnostic approaches covered in the report include:

Endoscopic evaluation
Histological examination (requiring ≥15 eosinophils per high-power field for confirmation)
Identification of endoscopic features (linear grooves, concentric rings, whitish exudates, Schatzki rings)
Esophageal mucosal biopsy analysis
Assessment of esophageal narrowing and strictures

Advancements in endoscopic imaging and standardized histological criteria are improving early detection and disease monitoring capabilities.

Treatment

The treatment landscape analysis includes the fundamental “3D” treatment concept:

Dietary Management:

Empirical food elimination diets
Guided food elimination based on allergy testing
Dietary modification to avoid dysphagia and food impaction

Pharmacologic Therapy:

Proton pump inhibitors (PPIs) as first-line treatment with response rates of 30–70%
Corticosteroid formulations including budesonide, fluticasone propionate, and ciclesonide
Immunosuppressive agents
Novel targeted biologic therapies

Mechanical Intervention:

Endoscopic bougie dilation
Balloon dilation for esophageal strictures
Periodic dilation as acceptable alternative therapy

Regional treatment guidelines and algorithms across the US, Europe, and Japan are provided to support standardized clinical decision-making.

Eosinophilic Esophagitis (EoE) Drug Chapters

The report provides comprehensive analysis of marketed products and emerging pipeline therapies under development for EoE treatment.

Marketed Therapies

The report covers currently available therapies and treatment options utilized in clinical practice for EoE management, including proton pump inhibitors, topical corticosteroids, and endoscopic dilation procedures.

Emerging Therapies

Budesonide Oral Suspension (Takeda/Shire) An oral viscous formulation of budesonide formulated specifically as an investigational treatment for EoE. Clinical trials demonstrate this formulation is more effective than nebulized or swallowed budesonide for improving esophageal eosinophil counts and endoscopic findings in adults. The US FDA has granted priority review, breakthrough therapy designation, and orphan designation. The company submitted a new drug application (NDA) based on pivotal Phase III trials ORBIT1 and ORBIT2, with additional Phase III continuation studies underway for adolescent and adult subjects.

Cendakimab (Bristol-Myers Squibb) A recombinant humanized, high-affinity, selective anti-interleukin-13 (IL-13) monoclonal antibody that binds an IL-13 epitope preventing its binding to both IL-13 receptor subtypes. The drug has been granted orphan drug designation for EoE treatment. Phase II studies demonstrated positive results, and Phase III clinical trials are currently evaluating efficacy and safety in adult and adolescent participants.

The pipeline section also evaluates additional late-stage and mid-stage therapies including:

Dupilumab (Regeneron Pharmaceuticals/Sanofi)
APT-1011 (Ellodi Pharmaceuticals)
Benralizumab (AstraZeneca)
Lirentelimab (Allakos)

The report further analyzes:

Clinical trial activities and endpoints
Pharmacological mechanisms of action
Licensing and collaboration agreements
Patent and regulatory developments
Recent company updates and strategic initiatives

Eosinophilic Esophagitis (EoE) Market Outlook

The Eosinophilic Esophagitis market outlook section delivers detailed insights into current and forecasted market trends by evaluating:

Existing and emerging therapies
Unmet clinical needs
Market drivers and barriers
Therapy-specific uptake trends
Competitive positioning of marketed and pipeline products

The report also assesses annual therapy costs, expected launch timelines, patient eligibility criteria, market penetration potential, and key opinion leader perspectives influencing future adoption trends.

According to DelveInsight, the Eosinophilic Esophagitis market across the 7MM is anticipated to undergo significant transformation during the forecast period 2018–2030.

Regional Eosinophilic Esophagitis Market OutlookUnited States Market Outlook

This section provides detailed analysis of the total EoE market size and therapy-specific market trends in the United States. The United States accounts for the highest market size of EoE in comparison to the EU5 countries and Japan. The market analysis includes:

PPIs as first-line treatment with initial doses of 20–40 mg or 1 mg/kg per dose administered twice daily
Corticosteroid efficacy in achieving histological remission
Bougie and balloon dilation as the only endoscopic treatment for persistent dysphagia
Current and forecasted therapy adoption trends

EU5 Market Outlook

Comprehensive market analysis is provided for Germany, France, Italy, Spain, and the United Kingdom, covering:

Current and forecasted therapy adoption trends
Regional variations in treatment approaches
Market dynamics and competitive landscape

Japan Market Outlook

The report also evaluates the EoE market dynamics and therapy landscape in Japan, providing insights specific to the Japanese healthcare system and treatment practices.

Eosinophilic Esophagitis (EoE) Drugs Uptake and Pipeline Development Activities

The report evaluates the expected uptake of recently launched and upcoming therapies during the study period 2018–2030. The analysis focuses on:

Patient uptake trends by therapy type
Therapy adoption rates across regions
Market share analysis
Commercial potential of pipeline candidates
Reasons behind maximal use of new drugs
Comparison of drugs based on market share and size

Additionally, the report highlights:

Phase III, Phase II/III, Phase II, and Phase I/II pipeline candidates
Collaborations and licensing agreements
Mergers and acquisitions
Patent activities
Strategic partnerships influencing market expansion
Key players involved in developing targeted therapeutics

Reimbursement Scenario in Eosinophilic Esophagitis (EoE)

The report provides valuable reimbursement insights supporting strategic market access planning. It evaluates pricing and reimbursement challenges across key geographies while identifying commercially attractive markets with lower reimbursement barriers and favorable payer policies.

KOL Views and Competitive Intelligence Analysis

To validate secondary research findings and assess evolving treatment trends, DelveInsight incorporates perspectives from key opinion leaders (KOLs) and subject matter experts working in the EoE domain. These insights support understanding of current and emerging therapy treatment patterns and market trends.

The report also includes extensive competitive intelligence analysis utilizing tools such as:

SWOT Analysis
PESTLE Analysis
Porter’s Five Forces
BCG Matrix
Market Entry Strategies

These insights support stakeholders in identifying future opportunities and competitive positioning within the evolving market landscape.

Eosinophilic Esophagitis (EoE) Market Drivers and ChallengesKey Market Drivers

Increasing awareness and diagnosis of EoE
Rising prevalence of immune-mediated esophageal disorders
Advancements in endoscopic diagnostics and standardized histological criteria
Growing healthcare expenditure globally
Unmet clinical need for FDA-approved targeted therapies
Emerging biologic therapies offering improved efficacy
Rising incidence in young adults and children
Increasing research into improved treatment algorithms

Key Market Challenges

Lack of FDA-approved drugs specifically for EoE treatment
Variability in treatment response and disease natural history
Complexity of the “3D” treatment approach requiring multidisciplinary management
Limited uniform endpoints in clinical trials
Recurrence and relapse risks requiring long-term maintenance therapy
Need for deeper understanding of disease progression
Reimbursement and pricing challenges for emerging biologic therapies
Regional variations in treatment guidelines and practices

Download sample report now – https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=mpr

Eosinophilic Esophagitis (EoE) Report Scope

The report offers global coverage with focus on:

Historical and forecasted market trends from 2018 to 2030
Epidemiology analysis across the 7MM
Current and emerging therapies
Competitive landscape and pipeline assessment
Market drivers, barriers, and unmet needs
Strategic insights for stakeholders and healthcare companies
Detailed disease understanding and treatment algorithms
Comprehensive KOL perspectives and competitive intelligence

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance and strategic decision-making.

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Eosinophilic Esophagitis (EoE) Market to Witness Significant Growth Through 2030, Driven by Advancements in Diagnostics and Emerging Biologic Therapies, Reveals DelveInsight

Aicardi Goutières Syndrome Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Targeted Therapies and Rising Disease Awareness | DelveInsight

The market dynamics for Aicardi Goutières Syndrome (AGS) are evolving steadily due to increasing awareness of rare genetic interferonopathies, improvements in genetic diagnostic capabilities, and growing research activities focused on targeted immunomodulatory therapies. Additionally, the development of emerging therapies such as IMSB301 and advancements in JAK inhibitor-based treatment approaches are expected to further support the AGS market growth during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Aicardi Goutières Syndrome (AGS) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Aicardi Goutières Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Aicardi Goutières Syndrome Market

The market size for Aicardi Goutières Syndrome in the 7MM is expected to increase significantly by 2036 owing to the launch of emerging therapies and advancements in rare disease diagnostics.
The United States accounted for the highest AGS market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.
According to Orphanet (2024), more than 500 cases of AGS have been reported in the literature to date.
According to Hunter’s Hope (2025), roughly 400 cases of AGS were known as of 2014, and just over 120 cases had been reported in medical literature. The early-onset form affects around 20% of babies affected by AGS.
An article by the National Health Service (2021) highlighted that AGS is the most common monogenic interferonopathy, with an estimated prevalence in England of 1 in 110,000.
As per a study conducted by Shoaff et al. (2022), AGS affects less than 1 in 100,000 newborns.
Leading AGS companies, such as ImmuneSensor Therapeutics and others, are developing novel therapies to improve outcomes in AGS patients.
The promising AGS therapies in clinical trials include IMSB301 and other targeted interferonopathy therapies.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/aicardi-goutieres-syndrome-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Aicardi Goutières Syndrome Market

Increasing Awareness and Improved Genetic Diagnosis:Growing recognition of interferonopathies and advancements in genetic testing technologies are improving the diagnosis of AGS globally. Early identification of TREX1, RNASEH2B, RNASEH2C, RNASEH2A, SAMHD1, ADAR, IFIH1, and RNU7-1 mutations is supporting earlier intervention and disease management.

Growing Interest in Targeted Immunomodulatory Therapies:Therapeutic approaches such as JAK inhibitors, immune-modulation therapies, antiretrovirals, and anti-IFN-alpha antibodies are being increasingly explored to manage AGS symptoms and underlying inflammation pathways.

Emergence of Novel Pipeline Therapies:The AGS pipeline, although limited, is witnessing progress with therapies such as IMSB301, a novel orally available cGAS inhibitor developed by ImmuneSensor Therapeutics. The therapy aims to suppress cytokine production and prevent pathological inflammation associated with AGS.

Aicardi Goutières Syndrome Competitive Landscape

The AGS pipeline includes emerging therapies such as IMSB301 (ImmuneSensor Therapeutics) and others focused on modulating interferon signaling pathways and reducing inflammatory responses. IMSB301 is a novel orally available small molecule designed to inhibit the cGAS enzyme and suppress disease-causing inflammation in AGS and other Type I interferonopathies.

These therapies are expected to address the major unmet need in AGS, where no approved disease-modifying therapies currently exist and treatment remains largely supportive.

Discover more about therapies set to grab major Aicardi Goutières Syndrome market share @Aicardi Goutières Syndrome Treatment Landscape

Recent Developments in the Aicardi Goutières Syndrome Market

In February 2026, ImmuneSensor Therapeutics announced that it dosed the first patient with IMSB301 in a Phase Ib clinical study in Australia involving genetically defined AGS and other Type I interferonopathies patients.
In November 2024, the US FDA granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to IMSB301 for the treatment of cGAS-driven Type I interferonopathy, AGS.

What is Aicardi Goutières Syndrome?

Aicardi Goutières Syndrome (AGS) is a rare hereditary leukodystrophy and monogenic interferonopathy characterized by severe neurological dysfunction and systemic inflammation. Symptoms usually appear within the first six months of life, although some cases may present later. AGS is associated with developmental delay, microcephaly, seizures, dystonia, feeding difficulties, and skin lesions such as chilblains. The disease often results in profound disability and can be life-threatening.

Aicardi Goutières Syndrome Epidemiology Segmentation

The AGS epidemiology section provides insights into the historical and current AGS patient pool and forecasted trends across the 7MM. The AGS market report offers epidemiological analysis for the study period 2022–2036 segmented into:

Total Incident and Diagnosed Prevalent Cases of AGS
Type-specific Cases of AGS (early-onset and late-onset)
Mutation-specific Cases of AGS
Country-specific AGS Patient Population

Scope of the Aicardi Goutières Syndrome Market Report

Therapeutic Assessment: AGS current and emerging therapies
AGS Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: ImmuneSensor Therapeutics and others
Key Therapies: IMSB301 and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, AGS Market Access and Reimbursement

To know more about Aicardi Goutières Syndrome companies working in the treatment market, visit @Aicardi Goutières Syndrome Clinical Trials and Therapeutic Assessment

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aicardi Goutières Syndrome Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Targeted Therapies and Rising Disease Awareness | DelveInsight

Interstitial Cystitis Market is Expected to Witness Significant Growth by 2036 Due to Rising Diagnosis Rates and Emerging Targeted Therapies | DelveInsight

The Interstitial Cystitis market is experiencing steady growth driven by increasing disease awareness, improving diagnosis rates, growing adoption of multimodal treatment strategies, and the development of novel targeted therapies. The emergence of pipeline candidates such as ALENURA (Vaneltix Pharma/Hyloris Pharma), ONO-1110 (Ono Pharmaceutical), SI-722 (Seikagaku Corporation), Sunobinop/V117957, and AKP-021 is expected to further strengthen the evolving treatment landscape.

DelveInsight, a leading market research and business consulting company, has released its latest report, “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast – 2036.” The report offers a comprehensive analysis of Interstitial Cystitis, covering epidemiology trends, current treatment practices, emerging therapies, market dynamics, and forecasted market growth across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Interstitial Cystitis Market Report

The Interstitial Cystitis market size in the 7MM is projected to grow steadily through 2036.
In 2025, the total diagnosed prevalent cases of Interstitial Cystitis in the 7MM were approximately 3.5 million.
The United States accounted for the largest Interstitial Cystitis market size among the 7MM in 2025, with more than USD 2 billion.
DelveInsight analysis indicates that the US represented more than 55% of total prevalent Interstitial Cystitis cases in the 7MM in 2025.
Within EU4 and the UK, Germany accounted for the highest market size at approximately USD 290 million in 2025.
In Japan, around 75% of Interstitial Cystitis cases were classified as mild, while 22% were moderate and nearly 3% severe in 2025.
Females represented approximately 60% of Interstitial Cystitis cases in the US in 2025, highlighting a clear female predominance.
The Interstitial Cystitis treatment landscape currently includes only two approved therapies, ELMIRON (Johnson & Johnson) and ZYMSO (Kyorin Pharmaceuticals), underscoring the major unmet need for safer and more effective therapies.
Leading companies developing Interstitial Cystitis therapies include Vaneltix Pharma/Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, and Aska Pharmaceutical.
Promising emerging therapies include ALENURA (lidocaine + heparin), ONO-1110, SI-722, Sunobinop (V117957), and AKP-021.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Interstitial Cystitis Market

Increasing Diagnosis Rates and Disease Awareness:- Growing awareness regarding chronic bladder pain syndromes, along with improved diagnostic approaches such as cystoscopy, urodynamics, and biomarker research, is contributing to earlier and more accurate diagnosis of Interstitial Cystitis.

Rising Adoption of Multimodal Treatment Approaches:- The management of Interstitial Cystitis increasingly relies on individualized treatment strategies involving oral medications, intravesical therapies, pelvic floor therapy, neuromodulation, behavioral modifications, and supportive care approaches.

Growing Demand for Novel and Safer Therapies:- Current therapies are often associated with limited efficacy and safety concerns. For example, long-term retinal toxicity risks associated with pentosan polysulfate sodium are increasing the demand for safer alternatives with improved clinical outcomes.

Advancements in Emerging Pipeline Therapies:- The pipeline for Interstitial Cystitis is expanding with innovative candidates targeting pain relief, inflammation control, bladder lining repair, and neuromodulation pathways. These emerging therapies are expected to reshape future treatment paradigms.

Interstitial Cystitis Competitive Landscape

The Interstitial Cystitis pipeline includes several promising candidates in mid- and late-stage clinical development such as ALENURA (Vaneltix Pharma/Hyloris Pharma), ONO-1110 (Ono Pharmaceutical), SI-722 (Seikagaku Corporation), Sunobinop/V117957 (Imbrium Therapeutics), and AKP-021 (Aska Pharmaceutical).
These therapies target diverse mechanisms including glycosaminoglycan stimulation, anti-inflammatory pathways, nociceptin/orphanin-FQ peptide receptor agonism, endocannabinoid regulation, and mPGES-1 inhibition. The growing focus on mechanism-based therapies reflects the increasing demand for more effective and personalized treatment options for Interstitial Cystitis patients.

Discover more about therapies set to grab major Bipolar Depression market share @ Interstitial Cystitis Treatment Landscape

Recent Developments in the Interstitial Cystitis Market

In March 2025, Hyloris announced a positive interim review outcome for the ALENURA clinical trial, with the Independent Data Monitoring Committee recommending continuation of the study. Patient enrollment is expected to be completed by the end of 2025.
In December 2024, Vaneltix Pharma initiated the VNX001-110 clinical trial to evaluate the safety, efficacy, and dosing frequency of ALENURA for Interstitial Cystitis treatment.
ALENURA currently holds patent protection until 2038, providing an extended commercialization opportunity window.
Japan continues to expand awareness and reimbursement access for therapies such as ZYMSO following its launch after NHI price listing approval.

What is Interstitial Cystitis?

Interstitial Cystitis is a chronic pelvic condition characterized by bladder pain, pressure, urinary urgency, frequency, and persistent inflammation without evidence of infection or other identifiable causes. Patients often experience severe discomfort, frequent urination, nocturia, and reduced quality of life. Diagnosis remains challenging because symptoms frequently overlap with other urinary and pelvic disorders, often resulting in delayed diagnosis.

Interstitial Cystitis Epidemiology Segmentation

The Interstitial Cystitis epidemiology section provides historical and forecasted epidemiological insights across the 7MM from 2022–2036, segmented into:

Total Prevalent Cases of Interstitial Cystitis
Total Diagnosed Prevalent Cases of Interstitial Cystitis
Age-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Gender-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Severity-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Type-specific Diagnosed Prevalent Cases of Interstitial Cystitis
Total Treated Cases of Interstitial Cystitis

Scope of the Interstitial Cystitis Market Report

Therapeutic Assessment: Current marketed and emerging Interstitial Cystitis therapies
Interstitial Cystitis Market Dynamics: Market drivers, barriers, and future opportunities
Key Companies: Johnson & Johnson, Kyorin Pharmaceuticals, Vaneltix Pharma, Hyloris Pharma, Ono Pharmaceutical, Seikagaku Corporation, Imbrium Therapeutics, Aska Pharmaceutical, and others
Key Therapies: ELMIRON, ZYMSO, ALENURA, ONO-1110, SI-722, Sunobinop (V117957), AKP-021, and others
Competitive Intelligence Analysis: SWOT analysis and market entry strategies
Unmet Needs, KOL perspectives, Analyst views, and Market Access & Reimbursement analysis

To know more about Bipolar Depression companies working in the treatment market, visit @ Interstitial Cystitis Market Clinical Trials and Therapeutic Assessment

Table of Contents

Key Insights
Report Introduction
Interstitial Cystitis Market Overview
Methodology of Epidemiology and Market
Executive Summary
Key Events
Disease Background and Overview
Epidemiology and Patient Population
Patient Journey
Marketed Therapies
Emerging Therapies
Interstitial Cystitis – 7MM Market Analysis
Key Opinion Leaders’ Views
SWOT Analysis
Unmet Needs
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers healthcare market research reports through its subscription-based platform PharmDelve.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Cystitis Market is Expected to Witness Significant Growth by 2036 Due to Rising Diagnosis Rates and Emerging Targeted Therapies | DelveInsight

Treatment-Resistant Depression Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Advancements in Novel Psychedelic-Based Therapies | DelveInsight

The market dynamics for Treatment-Resistant Depression (TRD) are expected to grow significantly due to the rising prevalence of depression, increasing cases unresponsive to standard antidepressants, greater mental health awareness, and advancements in psychedelic-based therapies. Emerging therapies such as COMP360, BPL-003, VLS-01, and the expanding adoption of SPRAVATO are further driving market growth.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Treatment-Resistant Depression (TRD) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of TRD, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Treatment-Resistant Depression (TRD) Market

The total market size of TRD in the 7MM was approximately USD 3,726 million in 2022 and is projected to reach nearly USD 5,874 million by 2036.
As per DelveInsight analysis, there were approximately 6.6 million prevalent cases of TRD across the 7MM in 2025, and this figure is projected to rise by 2036.
The United States accounted for nearly 71% of the patient share of TRD cases in the 7MM in 2025.
In 2025, an estimated 1.2 million males and 3.4 million females in the US were affected by TRD, indicating higher prevalence among females.
Germany reported the highest number of TRD cases among the EU4 and the UK in 2025, with approximately 600,000 prevalent cases.
Italy had the lowest prevalent population of TRD in 2025, with approximately 140 thousand cases.
The TRD treatment pipeline includes emerging therapies such as COMP360 by COMPASS Pathways, BPL-003 by Atai Beckley, and VLS-01 by Atai Beckley.
In January 2025, Johnson & Johnson announced that SPRAVATO (esketamine) received approval in the US as the first and only monotherapy specifically indicated for adults with TRD.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/treatment-resistant-depression-trd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Treatment-Resistant Depression Market

Increasing Burden of Depression and Treatment Resistance:A growing number of patients fail to respond adequately to conventional antidepressants despite appropriate treatment duration and dosage, significantly increasing the burden of TRD globally.

Advancements in Psychedelic-Based Therapies:The emergence of novel psychedelic-based therapies such as psilocybin and DMT-derived treatments is expected to transform the TRD treatment landscape by offering rapid and durable antidepressant effects.

Growing Adoption of Innovative Therapies:The increasing acceptance and clinical adoption of therapies such as SPRAVATO, transcranial magnetic stimulation (TMS), and other neuromodulation approaches are improving treatment outcomes in TRD patients.

Rising Awareness Regarding Mental Health Disorders:Improved awareness campaigns, expanded mental healthcare access, and growing recognition of depression-related disabilities are contributing to earlier diagnosis and better treatment access.

Treatment-Resistant Depression Competitive Landscape

Several companies are actively working to strengthen the TRD pipeline through innovative treatment approaches. Key companies involved in the TRD market include COMPASS Pathways, Atai Beckley, Johnson & Johnson, and others.
Promising therapies such as COMP360, BPL-003, and VLS-01 are currently being evaluated in clinical studies for their potential to deliver rapid antidepressant responses with durable efficacy.

Discover more about therapies set to grab major Treatment-Resistant Depression market share @ Treatment-Resistant Depression Treatment Landscape

Recent Developments in the Treatment-Resistant Depression Market

In May 2026, COMPASS Pathways announced that the Phase III COMP006 trial of COMP360 psilocybin in TRD met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in MADRS scores at Week 6.
In March 2026, Atai Beckley reported key clinical and regulatory updates for BPL-003 and announced plans to initiate Phase III development in Q2 2026 following a successful End-of-Phase II meeting with the FDA.
In November 2025, Atai Beckley reported positive Phase IIb open-label extension data for BPL-003, with the 12 mg dose showing sustained antidepressant effects for up to two months.
In January 2026, Johnson & Johnson presented new post-hoc Phase III analyses evaluating the effects of SPRAVATO on anhedonia in adults with TRD at the American College of Neuropsychopharmacology Annual Meeting.
In November 2025, Atai Beckley announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech focused on psychedelic-based neuroplastogens for mental health disorders.

What is Treatment-Resistant Depression (TRD)?

Treatment-Resistant Depression generally refers to a condition in which individuals do not respond adequately to at least one course of antidepressant therapy administered at appropriate doses and duration.

TRD is influenced by biological, psychological, and environmental factors including genetic predisposition, neurotransmitter imbalances, chronic stress, trauma, socioeconomic challenges, family conflicts, and comorbid conditions.

Current treatment approaches for TRD include pharmacological strategies such as switching or augmenting antidepressants, along with non-pharmacological treatments including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), and cognitive behavioral therapy (CBT).

Treatment-Resistant Depression Epidemiology Segmentation

The Treatment-Resistant Depression epidemiology section provides insights into the historical and current TRD patient pool and forecasted trends for the leading markets. The TRD market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

Total Prevalent Cases of TRD
Gender-specific Prevalent Cases of TRD
Age-specific Prevalent Cases of TRD
Diagnosed Prevalent Cases of MDD
Treatment Eligible Population
Treated Cases of MDD

Scope of the Treatment-Resistant Depression Market Report

Therapeutic Assessment: TRD current marketed and emerging therapies
TRD Market Dynamics: Key Market Forecast Assumptions and Market Outlook
Key Companies: COMPASS Pathways, Atai Beckley, Johnson & Johnson, and others
Key Therapies: SPRAVATO, COMP360, BPL-003, VLS-01, and others
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, TRD Market Access and Reimbursement

To know more about Treatment-Resistant Depression companies working in the treatment market, visit @ Treatment-Resistant Depression Clinical Trials and Therapeutic Assessment

Table of Contents

Treatment-Resistant Depression Market Report Introduction
Executive Summary for TRD
SWOT Analysis of TRD
TRD Patient Share (%) Overview at a Glance
TRD Market Overview at a Glance
TRD Disease Background and Overview
TRD Epidemiology and Patient Population
Country-Specific Patient Population of TRD
TRD Current Treatment and Medical Practices
TRD Unmet Needs
TRD Emerging Therapies
TRD Market Outlook
Country-Wise TRD Market Analysis (2022–2036)
TRD Market Access and Reimbursement of Therapies
TRD Market Drivers
TRD Market Barriers
TRD Appendix
TRD Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment-Resistant Depression Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Advancements in Novel Psychedelic-Based Therapies | DelveInsight

Food Packaging Market Worth $548.51 Billion by 2030, Growing at a CAGR of 5.4% – Report by MarketsandMarkets™

“MarketsandMarkets™”

Food Packaging Market by Material (Plastic, Paper & Paperboard, Glass, Metal, Other Materials), Packaging Type (Bags, Pouches, Bottles, Jars, Boxes, Trays, Clamshells, Other Packaging Types), Format (Flexible, Rigid, Semi-Rigid), Technology, Food Type, Application, Region – Global Forecast to 2030

The global food packaging market is projected to grow from USD 421.38 billion in 2025 to USD 548.51 billion by 2030, registering a CAGR of 5.4% during the forecast period, according to a new research report. The market is witnessing strong growth as food manufacturers increasingly adopt advanced packaging solutions to improve product safety, extend shelf life, and address the changing preferences of health-conscious and convenience-driven consumers. Packaging applications span across bakery & confectionery, dairy products, meat, poultry & seafood, fresh produce, convenience foods & ready meals, snacks & breakfast cereals, sauces & condiments, baby food, and other food categories including whole grains, cereals, pulses, and oils.

Food Packaging Market

Market Size and Growth Forecast

Market Size, 2024 (Value): USD 390.67 Billion
Market Forecast, 2030 (Value): USD 548.51 Billion
Growth Rate: CAGR of 5.4% from 2025 to 2030
Years Considered: 2020–2030
Base Year: 2024
Forecast Period: 2025–2030
Units Considered: Value (USD Million/Billion), Volume (Metric Tons)
Report Coverage: Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

The growing emphasis on food preservation, contamination prevention, and convenience is accelerating demand for innovative packaging formats. In addition, increasing adoption of sustainable materials, advancements in smart and active packaging technologies, and stringent food safety regulations are further supporting market expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=70874880

Rigid Packaging Segment Holds Significant Market Share

Based on format, the rigid packaging segment is estimated to account for a major share of the global food packaging market. Rigid packaging solutions, including glass, metal, and rigid plastic containers, continue to play a critical role due to their durability, versatility, and superior protective properties.

Glass jars and bottles are widely used for beverages, sauces, and preserved foods because they offer excellent protection against moisture, oxygen, and contaminants, helping extend product shelf life. Metal cans and tins remain preferred for canned foods and beverages owing to their strength, durability, and recyclability. Hard plastic containers are extensively utilized for dairy products, snacks, and ready-to-eat meals because of their lightweight and impact-resistant characteristics.

Consumer demand for packaging that maintains product quality and integrity, combined with growing adoption of recyclable and sustainable rigid materials, continues to drive the segment’s strong market presence globally.

Bottles Segment to Witness Strong Demand

By packaging type, bottles are projected to account for a significant share of the food packaging market. Bottles are extensively used across dairy products, sauces, condiments, and cooking oils due to their rigid structure, resealability, and compatibility with automated filling and sealing systems.

Materials such as PET, HDPE, and glass provide enhanced durability, barrier protection, and recyclability, supporting both product safety and shelf-life requirements. The segment has also benefited from innovations including lightweight packaging, tamper-evident closures, and advanced barrier coatings that improve functionality while reducing environmental impact.

Furthermore, regulatory initiatives aimed at reducing single-use plastics are encouraging the adoption of recyclable and bio-based bottle formats, particularly across North America and Europe. Rising demand for premium and health-focused food products is also increasing the need for packaging that enhances branding and shelf appeal.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=70874880

Europe Emerges as a Key Regional Market

Europe is expected to account for a notable share of the global food packaging market during the forecast period. The region benefits from a well-established food & beverage industry, advanced manufacturing infrastructure, and strong regulatory frameworks emphasizing food safety, quality, and sustainability.

Stringent regulations, including the European Union’s Food Contact Materials (FCM) framework and REACH regulations, continue to drive the adoption of safe and sustainable packaging solutions. Europe also remains at the forefront of sustainable packaging innovation, with growing investments in recyclable and biodegradable materials to meet increasing consumer demand for environmentally friendly products.

The presence of major packaging manufacturers across Switzerland, Finland, Ireland, and other European countries, along with efficient supply chains and distribution networks, further strengthens the region’s market position.

Leading Food Packaging Companies:

Key players operating in the food packaging market include Amcor Plc (Switzerland), Sealed Air (US), Mondi (UK), Tetra Pak International S.A. (Switzerland), Huhtamaki (Finland), Crown (US), Sonoco Products Company (US), DS Smith (UK), Silgan Containers (US), WestRock Company (US), Graphic Packaging International, LLC (US), International Paper (US), Smurfit Westrock (Ireland), ProAmpac (US), and Genpak (US).

Recent Developments in the Food Packaging Industry:

September 2025: Amcor Plc collaborated with Burts to launch a crisp (potato chip) packaging containing 55% post-consumer recycled (PCR) content using its AmFiniti solution under an ISCC-Plus mass balance approach. This material offered the same quality and performance as virgin resin, making it suitable and safe for food-grade applications without compromising product integrity. The pack maintained food-grade safety and barrier performance, enabling snack brands to integrate higher recycled content while aligning with sustainability goals.
January 2024: SEE launched CRYOVAC compostable overwrap tray and revolutionized food packaging with its biobased, USDA-certified resin and industrial compostability. This sustainable alternative to EPS foam trays maintained strength and performance while reducing environmental impact. The tray aligned with processors’ existing production lines, advancing SEE’s commitment to innovation, sustainability, and supporting customers’ eco-friendly goals in the protein packaging market.

Make an Inquiry: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=70874880

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/food-packaging-market-70874880.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/food-packaging-market-70874880.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Packaging Market Worth $548.51 Billion by 2030, Growing at a CAGR of 5.4% – Report by MarketsandMarkets™

Probiotics Market Worth USD 114.95 Billion by 2030, at a CAGR of 8.5% – Report by MarketsandMarkets™

“MarketsandMarkets™”

Probiotics Market Report by Product Type (Functional Food & Beverages (FnB), Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel, and Region Global Forecast to 2030

The global probiotics market is projected to grow from USD 76.59 billion in 2025 to USD 114.95 billion by 2030, registering a CAGR of 8.5% during the forecast period, according to a new research report. The probiotics market is witnessing sustained expansion as probiotics transition from niche wellness products into mainstream daily nutrition essentials. Manufacturers are increasingly incorporating probiotics into frequently consumed formats such as staple foods, beverages, and daily dietary supplements, driving repeat purchases and stabilizing long-term demand.

Probiotics Market

The growing consumer preference for science-backed ingredients, improved transparency regarding probiotic strain identity, and increasing healthcare professional involvement in probiotic recommendations are significantly contributing to market growth. This shift from occasional consumption toward consistent daily use is creating predictable volume demand and strengthening long-term market stability.

In addition, the probiotics industry is benefiting from stronger integration across the food, nutrition, and healthcare value chains. Probiotic ingredient suppliers are collaborating closely with downstream manufacturers during product development stages, enabling faster commercialization and customized applications. Investments in regional production facilities, contract manufacturing, and localized formulation hubs are further improving supply chain efficiency and reducing lead times, supporting diversified and sustainable market growth.

Technological advancements remain a key driver shaping the probiotics market. Innovations in microbial screening, genomics-based strain discovery, fermentation technologies, and product stabilization are enabling manufacturers to develop highly targeted probiotic solutions for digestive health, immunity, pediatrics, and metabolic wellness applications. Enhanced fermentation and downstream processing technologies are also improving scalability, production consistency, and regulatory compliance across global markets.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69

Hypermarkets/Supermarkets Segment Leads Distribution Channel

Based on distribution channel, the hypermarkets/supermarkets segment accounts for the largest share of the probiotics market. These retail outlets continue to dominate probiotic product sales due to strong product visibility, extensive consumer reach, and the convenience of one-stop shopping for food, beverages, and health products.

Strategic shelf placement alongside dairy products, beverages, and wellness foods enhances consumer familiarity and encourages trial purchases. Large retail chains also support manufacturers through centralized procurement systems, promotional campaigns, private-label offerings, and bundled sales strategies that help accelerate market penetration and increase product volumes.

Although pharmacies and e-commerce channels are gaining momentum in probiotic supplement sales, supermarkets remain the preferred channel for probiotic foods and beverages due to established cold-chain infrastructure and frequent consumer shopping cycles.

Food & Beverages Segment Holds Largest Market Share

By product type, the food & beverages segment dominates the probiotics market owing to high consumption frequency and integration into daily dietary habits. Probiotic yogurts, fermented milk drinks, dairy products, and emerging plant-based probiotic beverages have significantly contributed to probiotics becoming part of routine nutrition rather than occasional supplementation.

Consumers increasingly perceive probiotic foods as preventive wellness solutions that support long-term health, encouraging repeat consumption. Major food manufacturers continue to leverage strong retail networks, trusted brands, and advanced cold-chain systems to scale probiotic food offerings more rapidly than standalone supplements.

Additionally, ongoing product innovation, flavor diversification, and the growing popularity of plant-based probiotic beverages are expanding the consumer base across multiple demographic groups, including children and older adults.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=69

Asia Pacific Emerges as Largest Regional Market

The Asia Pacific region accounts for the largest share of the global probiotics market, supported by longstanding consumption habits, rising gut health awareness, and strong participation from both regional and multinational manufacturers.

Japan continues to serve as a key market, led by companies such as Yakult Honsha Co., Ltd., which has expanded localized production and distribution across Southeast Asia. In China, major dairy and nutrition companies including Danone S.A. have strengthened investments in specialized nutrition and fermented dairy production to address growing demand for digestive and pediatric health products.

India is also emerging as a high-growth market, with companies such as Nestlé S.A. expanding probiotic dairy and nutrition portfolios through new product launches and local sourcing initiatives. Simultaneously, domestic ingredient suppliers and regional brands are increasing investments in fermentation and formulation technologies to strengthen market competitiveness.

Rapid urbanization, modernization of retail infrastructure, and increasing consumer focus on preventive healthcare continue to position Asia Pacific as the leading growth engine for the global probiotics market.

Leading Probiotics Companies:

The probiotics market is characterized by the presence of major global ingredient suppliers, fermentation specialists, and food technology companies with strong expertise in microbial science and formulation engineering.

Key players operating in the market include Novonesis (Denmark), ADM (US), International Flavors & Fragrances – IFF (US), Kerry Group (Ireland), Lallemand (Canada), Yakult Honsha (Japan), and BioGaia (Sweden).

These companies are heavily investing in strain development, clinical validation, fermentation optimization, and scalable production technologies to strengthen global market positioning. Collaboration among probiotic suppliers, academic institutions, and healthcare research organizations continues to drive innovation in strain functionality, stability, and delivery technologies.

Furthermore, advancements in freeze-drying, protective coating technologies, and formulation science are enabling probiotics to maintain stability during processing, storage, and gastrointestinal transit, thereby supporting wider applications across food, beverage, supplement, infant nutrition, and medical nutrition sectors.

As consumer demand for preventive healthcare and functional nutrition continues to rise globally, the probiotics market is expected to witness sustained long-term growth driven by technological innovation, product diversification, and expanding mainstream adoption.

Regional Analysis:

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: https://www.marketsandmarkets.com/Market-Reports/probiotics-market-69.html
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/probiotics-market-69.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Probiotics Market Worth USD 114.95 Billion by 2030, at a CAGR of 8.5% – Report by MarketsandMarkets™